Business Wire

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

Jaa

HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today that Peter W. Macfarlane has joined its board of clinical advisors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180502005011/en/

HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)

HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)

Professor Peter W. Macfarlane, DSc eFESC FRSE, is an expert in the field of electrocardiology and has over 40 years’ experience in the development of computer-based systems for the interpretation of ECGs. He has authored over 300 publications and peer-reviewed papers, as well as numerous books on the subject. Professor Macfarlane is recognized as a pioneer in the use of computers in hospital-based ECG interpretation. The work of his team has been adopted commercially, and the University of Glasgow ECG interpretation analysis developed in his laboratory is currently used worldwide. The Glasgow analysis is incorporated in the MyoVista® wavECG™ Device where it complements HeartSciences by providing computerized analysis of the conventional ECG waveform. At present, he is Emeritus Professor and Honorary Senior Research Fellow of the University of Glasgow. In 2014, Professor Macfarlane was awarded a CBE for services to British healthcare.

Peter is the current President of the International Society of Computerized Electrocardiology (ISCE). He also serves as Treasurer of the International Society of Electrocardiology (ISE), having been President in the past. His major interest throughout his career has been the application of computer techniques to ECG interpretation.

“HeartSciences’ use of computerized techniques, such as signal processing and artificial intelligence, is truly innovative. I look forward to contributing to HeartSciences’ success,” said Macfarlane.

“HeartSciences is honored to have Peter join our Clinical Advisory Board. His wealth of experience and expertise in the application of computer techniques in electrocardiology aligns well with the company’s technology and vision for the future,” said Mark Hilz, chief executive officer of HeartSciences. “We look forward to working with Peter to achieve our shared goals of improving ECG capabilities for the detection of heart disease.”

About HeartSciences

HeartSciences is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market, 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy-related information rather than conventional voltage-based data. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to proprietary informatics, the MyoVista wavECG Device has full, 12-lead resting ECG capabilities, including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive processes. The device has a 15.6-inch, high-resolution touchscreen display and incorporates many features commonly associated with a tablet device, requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

Contact information

HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com
or
Investor Contact
Zimmons International Communications
Jennifer K. Zimmons, +1-917-214-3514
jzimmons@zimmonsic.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Abu Dhabi to Host Interfaith Alliance For Safer Communities: Child Dignity in the Digital World Forum on 19 November17.11.2018 16:40Tiedote

Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, the UAE will host the first edition of the Interfaith Alliance For Safer Communities Forum on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181117005008/en/ His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (Photo: AETOSWire) The forum will host 450 guests including religious leaders, NGOs and heads of industry to discuss ongoing social challenges and develop comprehensive solutions for protecting youth from cybercrime. The Interfaith Alliance For Safer Communities Forum is an expansion of the Child Dignity in the Digital World Congress which was held in October 2017 in the Vatican, an

Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 14:00Tiedote

Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r

Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 21:00Tiedote

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 17:33Tiedote

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 16:55Tiedote

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 16:15Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme